Opportunities
PresolicitationAccepting responses

RNA sequencing and whole genome sequencing services

National Institutes of Health · NATIONAL INSTITUTES OF HEALTH OLAO

Respond by: Nov 6, 2026, 9:00 AM UTC−57 days left

From SAM.gov's public data file generated Oct 29, 2026, 3:30 AM UTC; newest notice posted Oct 29, 2026; loaded into FedSub Oct 29, 2026, 5:46 AM UTC

Notice facts

Source: SAM.gov Contract Opportunities public data file

Solicitation number
75N98027Q00043
Notice type
Presolicitation
Posted
Oct 28, 2026
Response date
Respond by Nov 6, 2026, 9:00 AM UTC−5
Set-aside
No Set aside used
NAICS code
None stated
Product or service code
Q301
Place of performance
Bethesda, MD 20892
Contracting office
NATIONAL INSTITUTES OF HEALTH OLAO (75N980)BETHESDA, MD 20892
Agency
Department of Health and Human Services · National Institutes of Health

Past prime awardees

Source: Award history, not a list of bidders on this notice

Past prime awardees · award history, not a list of bidders on this notice

This notice lists no NAICS code, so FedSub can't match past awardees.

Description

Source: SAM.gov Contract Opportunities public data file

NOTICE OF INTENT – SOLE-SOURCE ACQUISITION Notice No.: 75N98027Q00020 The National Institutes of Health (NIH), National Cancer Ibstitute (NCI), intends to award a Firm-Fixed-Price Purchase Order to Plasmidsaurus Inc. for RNA sequencing and whole genome sequencing services for various wild-type, drug-treated cell lines and samples related to CRISPR research. Description of the Requirement The primary objective of this study is to investigate common lymphoma-related translocations involving MYC, BCL6, or BCL2, while also examining copy number alterations and making CNV calls for genes of interest. To achieve this, RNA sequencing will be provided for samples generated in the Staudt laboratory. RNA sequencing is essential for characterizing genome edits and conducting transcriptomic analysis. By utilizing Plasmidsaurus, a faster and more scalable alternative to traditional sequencing methods based on the latest Oxford Nanopore Technologies platform, we aim to generate results that will deepen our understanding of cellular mechanisms involved in B-cell lymphoma and guide future downstream experiments. RNA sequencing and Whole-genome sequencing are required to observe the effects of various drugs on gene expression, identify pathways, and discover novel pathways. Justification for the Proposed Sole-Source Acquisition The Government intends to solicit from a single source pursuant to FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. Plasmidsaurus uses the latest Oxford Nanopore Technologies platform, a faster, more scalable alternative to traditional sequencing. Using the latest Oxford Nanopore Technologies platform ensures accurate sequencing, which is crucial for reproducible experiments which will significantly advance our understanding of, and treatment for, B-cell lymphoma, which is vital to cancer research at the National Cancer Institute. Response Information This notice is not a request for competitive…

SAM.gov's data file removes line breaks; read the formatted notice and attachments on SAM.gov.

Versions on SAM.gov

Source: SAM.gov Contract Opportunities public data file

  1. Posted Oct 28, 2026PresolicitationCurrent version

    Respond by Nov 6, 2026, 9:00 AM UTC−5

    This version on SAM.gov (opens SAM.gov in a new tab)

Sources

  • SAM.gov Contract Opportunities public data file: file generated Oct 29, 2026, 3:30 AM UTC
  • USAspending.gov prime contract awards, as loaded into FedSub: actions through Oct 25, 2026
  • USAspending.gov first-tier subaward reports (FFATA): reports through Sep 30, 2026
  • Your partner preferences and your company's records on FedSub

Notices posted or changed after SAM.gov generated its file appear in FedSub after the next load. Check SAM.gov for the current version before you respond.

Source: SAM.gov Contract Opportunities public data file. FedSub is not affiliated with SAM.gov or GSA.